The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

U.S. stock futures slipped on Monday night as the market awaited clarity from President Donald Trump regarding his tariff policy rollout. Futures tied to the Dow Jones Industrial Average fell by 86 ...

It was last up about 4.6%. Lilly's shares fell more than 3%. Shares of Novo Nordisk, which makes rival GLP-1 drug Wegovy, were down about 2%. Hims had been selling less expensive versions of ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in ...

Danish drugmaker Novo Nordisk’s injectable semaglutide – sold under brand names Ozempic and Wegovy –may also be launched in India sometime this year. The innovator hasn’t clarified a ...

The announcement came as Novo Nordisk announced it was expanding its offer for cash-paying patients to access to its Wegovy (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at ...

Wegovy was approved to treat obesity in June 2021, and it is available as an injection in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg of the once-weekly, single-dose pen. Its list price is $1,349, and ...